VP-001 is under clinical development by PYC Therapeutics and currently in Phase I for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase I drugs for Retinitis Pigmentosa (Retinitis) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VP-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VP-001 overview
VP-001 is under development for the treatment of retinitis pigmentosa type 11 (RP11). The drug candidate is being developed based on cell-penetrating peptides (CPPs) delivery platform. It acts by targeting U4/U6 small nuclear ribonucleoprotein (PRPF31) gene. It is administered through intravitreal route.
PYC Therapeutics overview
PYC Therapeutics (PYCTX) is a biotechnology company. The company develops intracellular biological therapeutics. It utilizes proprietary phylomer peptide libraries and screening methodologies to identify unique peptide drug candidates. The company’s products include libraries and peptides. PYCTX had RNA-targeted therapeutics design capabilities which are supported by revolutionary delivery technology based on Cell-Penetrating Peptides (CPPs) to overcome the challenges in genomic therapies. The company’s product pipeline includes VP-001, VP-002, PYC-001, and Multiple for eye and multiple for CNS. It has three defined preclinical programs for Inherited Retinal Diseases, and a strong focus on Central Nervous System diseases. PYCTX is headquartered in Nedlands, Western Australia, Australia.
For a complete picture of VP-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
